Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Operating Income: 2023-2024

Historic Operating Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$50.9 million.

  • Contineum Therapeutics' Operating Income fell 76.18% to -$17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$50.9 million, marking a year-over-year decrease of 416.57%. This contributed to the annual value of -$50.9 million for FY2024, which is 416.56% down from last year.
  • Contineum Therapeutics' Operating Income amounted to -$50.9 million in FY2024, which was down 416.56% from $16.1 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Operating Income registered a high of $16.1 million during FY2023, and its lowest value of -$50.9 million during FY2024.
  • In the last 2 years, Contineum Therapeutics' Operating Income had a median value of -$17.4 million in 2023 and averaged -$17.4 million.
  • Data for Contineum Therapeutics' Operating Income shows a maximum YoY plummeted of 416.56% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Operating Income (Yearly) stood at $16.1 million in 2023, then tumbled by 416.56% to -$50.9 million in 2024.